405 related articles for article (PubMed ID: 27535663)
21. Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation.
Melenhorst JJ; Tian X; Xu D; Sandler NG; Scheinberg P; Biancotto A; Scheinberg P; McCoy JP; Hensel NF; McIver Z; Douek DC; Barrett AJ
Haematologica; 2012 Jun; 97(6):867-73. PubMed ID: 22133778
[TBL] [Abstract][Full Text] [Related]
22. Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow.
Adamiak M; Borkowska S; Wysoczynski M; Suszynska M; Kucia M; Rokosh G; Abdel-Latif A; Ratajczak J; Ratajczak MZ
Oncotarget; 2015 Aug; 6(22):18819-28. PubMed ID: 26299919
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
[TBL] [Abstract][Full Text] [Related]
24. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G
J Clin Oncol; 2019 Feb; 37(5):367-374. PubMed ID: 30523748
[TBL] [Abstract][Full Text] [Related]
27. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
[TBL] [Abstract][Full Text] [Related]
28. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Chaudhry HM; Bruce AJ; Wolf RC; Litzow MR; Hogan WJ; Patnaik MS; Kremers WK; Phillips GL; Hashmi SK
Biol Blood Marrow Transplant; 2016 Apr; 22(4):605-616. PubMed ID: 26409924
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
[TBL] [Abstract][Full Text] [Related]
30. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ
Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630
[TBL] [Abstract][Full Text] [Related]
31. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
32. Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases.
Wang HX; Yan HM; Wang ZD; Xue M; Liu J; Guo ZK
Leuk Lymphoma; 2012 Apr; 53(4):654-9. PubMed ID: 21929286
[TBL] [Abstract][Full Text] [Related]
33. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
35. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
36. Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Michelis FV; Hedley DW; Malhotra S; Chow S; Loach D; Gupta V; Kim DD; Kuruvilla J; Lipton JH; Viswabandya A; Messner HA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1158-1163. PubMed ID: 30654137
[TBL] [Abstract][Full Text] [Related]
37. CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation.
Demirer T; Ilhan O; Arat M; Genç Y; Ozcan M; Dalva K; Celebi H; Beksaç M; Akan H; Gürman G; Konuk N; Uysal A; Arslan O; Koç H
J Clin Apher; 2001; 16(2):67-73. PubMed ID: 11746531
[TBL] [Abstract][Full Text] [Related]
38. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
39. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
Sawada H; Wake A; Yamasaki Y; Izumi Y
Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
[TBL] [Abstract][Full Text] [Related]
40. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.
Chabannon C; Bijou F; Miclea JM; Milpied N; Grouin JM; Mohty M
Transfusion; 2015 Sep; 55(9):2149-57. PubMed ID: 25968564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
